Consun Pharmaceutical Group Limited (FRA:C1P)

Germany flag Germany · Delayed Price · Currency is EUR
1.490
+0.330 (28.45%)
At close: Jul 18, 2025, 10:00 PM CET
261.65%
Market Cap1.12B
Revenue (ttm)392.66M
Net Income (ttm)120.48M
Shares Outn/a
EPS (ttm)0.14
PE Ratio9.31
Forward PE9.08
Dividend0.03 (2.25%)
Ex-Dividend DateJun 10, 2025
Volume1,433
Average Volume1,011
Open1.170
Previous Close1.160
Day's Range1.170 - 1.490
52-Week Range0.392 - 1.490
Betan/a
RSI67.30
Earnings DateAug 22, 2025

About FRA:C1P

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 3,164
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol C1P
Full Company Profile

Financial Performance

In 2024, FRA:C1P's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.